<DOC>
	<DOCNO>NCT01333605</DOCNO>
	<brief_summary>The aim study prove IGEV regimen follow autologous stem cell transplantation salvage treatment patient refractory relapse Hodgkin lymphoma effective .</brief_summary>
	<brief_title>IGEV Followed Autologous Transplantation Refractory Relapsed Hodgkin Lymphoma</brief_title>
	<detailed_description>The standard treatment patient refractory relapse Hodgkin lymphoma salvage chemotherapy follow autologous transplantation responsive patient . However , standard salvage chemotherapy remain uncertain . This study evaluate efficacy safety IGEV regimen single-center basis .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Age range : 1865 year old Histological confirm refractory relapse Hodgkin lymphoma With least one site measurable disease accord IWC criterion ECOG performance status 01 Life expectancy 3 month Bone marrow function : ANC≧1.5×109/L , PLT≧100×109/L , Hb≧80g/L Liver function : total bilirubin , ALT AST &lt; 1.5×UNL Renal function : Cr &lt; 1.5×UNL , CCR≧45ml/min No contraindication transplantation No prior chemotherapy With 2 line prior chemotherapy exposure Evidence CNS bone marrow involvement History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Pregnant lactate woman Significant active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>IGEV</keyword>
	<keyword>Autologous stem cell transplantation</keyword>
</DOC>